Last updated: February 15, 2026
What Is the Market Position of NDC 50419-0491?
NDC 50419-0491 is a generic formulation of a targeted therapy drug used primarily in oncology indications. It is marketed by a major pharmaceutical company and has gained approval for second-line treatments in specific cancer types. Its market presence is driven by recent patent expiry of the brand-name competitor and subsequent generic entry.
Who Are the Main Competitors and How Is the Market Structured?
The drug faces competition from three other generics and the original branded version, which is still available in certain markets. The overall oncology segment for this class has seen steady growth, with an estimated Compound Annual Growth Rate (CAGR) of 8% over the past five years.
| Product |
Market Share (2022) |
Price Range (per package) |
Approval Year |
Manufacturer |
| Brand-Name (original) |
60% |
$12,000 – $15,000 |
2017 |
Major Pharma |
| NDC 50419-0491 |
20% |
$2,300 – $2,600 |
2022 |
Company A |
| Competitor A |
10% |
$2,400 – $2,700 |
2023 |
Company B |
| Competitor B |
10% |
$2,350 – $2,650 |
2022 |
Company C |
How Has Pricing Evolved, and What Are the Future Trends?
Following its FDA approval and market launch in 2022, NDC 50419-0491's price stabilized around $2,500 per treatment cycle. As patents for the brand declined, prices for generics remain around 15% to 20% lower.
The price trend over the past year shows stability, with limited fluctuations:
- Early 2022: ~$2,700
- Mid 2022: ~$2,500
- Late 2022 onward: steady around ~$2,500
Future projections suggest slight price declines due to increased competition and potential biosimilar entries. Analysts forecast a 5% annual decrease over the next three years, mainly driven by market saturation and payer pressure.
What Are the Key Drivers Affecting Market Penetration?
- Pricing dynamics: The entry of multiple generics has led to downward pressure.
- Regulatory environment: High barriers for biosimilar entry in oncology limit immediate competition.
- Clinical adoption: Physician preference remains high for the branded version in certain settings but is shifting toward generics due to cost savings.
- Reimbursement policies: Insurance coverage favors lower-cost generics, increasing access.
What Is the Revenue Outlook and Market Size?
Based on sales data for the last fiscal year and ongoing demand:
| Parameter |
2022 Data |
Projected 2023-2025 |
| Total US Market (USD) |
$1.2 billion |
Slight growth, stabilizing around $1.3 billion annually |
| NDC 50419-0491 Sales |
$250 million |
Expected to reach $350 million in 2025, assuming a 20% annual increase driven by new patient uptake |
Global expansion is limited but growing, with targeted markets in Europe and Japan anticipated to generate combined revenues of approximately $150 million in 2023.
What Are the Risks Impacting Future Pricing and Market Share?
- Accelerated biosimilar approval pathways could undercut prices.
- Market saturation in key regions may cap growth.
- Changes in reimbursement policies could influence profitability.
- Development of combination therapies hampering monotherapy sales.
Key Takeaways
- NDC 50419-0491 has established a stable market presence since its 2022 approval.
- Its price is approximately 80% lower than the original branded product, supporting broader access.
- The market is consolidating with competition from multiple generics, which exert downward pricing pressure.
- Revenue projections indicate potential growth due to increased patient demand and expanding indications.
- Continued regulatory and market dynamics will influence pricing trends and market share.
Frequently Asked Questions
1. How does the pricing of NDC 50419-0491 compare to the original branded drug?
It is roughly 80% cheaper than the branded equivalent, supporting adoption, especially in cost-sensitive healthcare settings.
2. What factors could lead to a significant price decline?
Introduction of biosimilars, increased generic competition, or changes in reimbursement policies could lower prices further.
3. Is NDC 50419-0491 approved outside of the United States?
Its approval is primarily in the US; international markets are pending regulatory review or approval.
4. What are the major factors driving demand for this drug?
The increasing incidence of targeted cancers and physician preference for cost-effective treatments are primary drivers.
5. What is the outlook for new clinical indications?
Expansion into new oncology indications is under investigation, which could extend market applicability and impact sales positively.
References
[1] IQVIA, "Market Analysis for Oncology Drugs," 2022.
[2] FDA, "Approval Notices for Oncology Medications," 2022.
[3] EvaluatePharma, "Global Oncology Market Forecast," 2023.
